We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds
Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds
Health

Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds

Last updated: February 19, 2025 12:28 pm
Editorial Board Published February 19, 2025
Share
SHARE

Credit score: Unsplash/CC0 Public Area

A examine performed utilizing digital well being report knowledge from a collective of U.S. well being care techniques discovered that the majority adults with obese or weight problems discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) remedy inside one yr. Discontinuation charges had been considerably greater and reinitiation charges had been considerably decrease for sufferers with out kind 2 diabetes.

GLP-1 RAs are used for weight administration and glycemic management, with proof suggesting that continued use is critical for sustained advantages. Considerations associated to value, tolerability, and entry could also be contributing to excessive discontinuation charges. Earlier research have reported broadly various discontinuation charges, however knowledge on reinitiation patterns stay restricted.

Within the examine, “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity,” printed in JAMA Community Open, researchers investigated the charges at which individuals stopped utilizing the favored weight reduction medicine.

A retrospective cohort evaluation included 125,474 adults with obese or weight problems who initiated remedy with liraglutide, semaglutide, or tirzepatide between January 1, 2018, and December 31, 2023. Eligible sufferers had a physique mass index of 27 or greater, a weight measurement inside 60 days earlier than initiation, and common well being care interactions within the earlier yr.

Discontinuation was outlined as 60 days with none GLP-1 RA available. Reinitiation was outlined as the primary fill of any GLP-1 RA after discontinuation. Sufferers had been adopted for as much as two years for discontinuation and two further years for reinitiation. Time-to-event outcomes had been assessed utilizing Kaplan-Meier fashions and Cox proportional hazards regression.

Rates of stopping and restarting GLP-1 therapy explored

Proportions Discontinuing and Reinitiating Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Inside 2 Years. Credit score: JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2024.57349

Inside one yr, 46.5% of sufferers with kind 2 diabetes and 64.8% with out kind 2 diabetes discontinued GLP-1 RA remedy. Inside two years, discontinuation charges elevated to 64.1% and 84.4%, respectively. Gastrointestinal antagonistic occasions had been linked to the discontinuation charges.

Amongst 41,792 sufferers who discontinued and had a weight measurement at discontinuation, 47.3% of sufferers with kind 2 diabetes and 36.3% with out kind 2 diabetes reinitiated remedy inside one yr. Weight regain was considerably related to reinitiation, with a 1% weight achieve rising the hazard by 2.3% for sufferers with kind 2 diabetes and a pair of.8% for these with out. Sufferers aged 65 years or older had been much less prone to reinitiate remedy.

GLP-1 RA discontinuation charges had been excessive, notably for sufferers with out kind 2 diabetes, who additionally had decrease reinitiation charges. Weight reduction throughout remedy was related to decrease discontinuation, whereas weight regain after discontinuation was linked to greater reinitiation.

Extra info:
Patricia J. Rodriguez et al, Discontinuation and Reinitiation of Twin-Labeled GLP-1 Receptor Agonists Amongst US Adults With Obese or Weight problems, JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2024.57349

© 2025 Science X Community

Quotation:
Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds (2025, February 19)
retrieved 19 February 2025
from https://medicalxpress.com/information/2025-02-adults-glp-therapy-year-restart.html

This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

AI-powered digital staining of biopsies for transplant diagnostics

New examine maps 4 key pathways to Alzheimer’s illness

A mathematical perspective presents perception into the placenta’s position and functioning

‘Chaotic and deeply horrifying’: As soon as a world gold commonplace, US authorities well being steering is falling aside

How physique mass index impacts breast most cancers threat in postmenopausal ladies with and with out heart problems

TAGGED:adultsanalysisfindsGLP1ratesrestartstoptherapyyear
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Up to date American Academy of Neurology place assertion issued on seizures, driving licensure
Health

Up to date American Academy of Neurology place assertion issued on seizures, driving licensure

Editorial Board March 30, 2025
Former VP Mike Pence attacked on X for calling out Trump’s Ukraine lies
What Happens if Roe v. Wade Is Overturned? Key Questions and Answers.
What Can Historical past Museums Provide within the Trump Period? 
101-Year-Old Ex-Guard at Nazi Camp Is Convicted by German Court

You Might Also Like

Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse
Health

Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse

July 7, 2025
Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas
Health

Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas

July 7, 2025
Lacking useful micro organism in toddler guts linked to rising bronchial asthma and allergy instances
Health

Lacking useful micro organism in toddler guts linked to rising bronchial asthma and allergy instances

July 7, 2025
How AI helps researchers to demystify intestine micro organism
Health

How AI helps researchers to demystify intestine micro organism

July 7, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?